vistrutide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

Investigational long-acting GLP-1/GIP/glucagon triple receptor agonist peptide compound Reference needs_revision Best effort · source review pending

Also known as: UBT251, UBT-251, UBT 251

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Best-Effort Research Profile

UBT251 is an investigational long-acting synthetic peptide being developed for obesity, type 2 diabetes, and related metabolic conditions. Developer and clinical-trial sources describe it as a triple agonist at the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. The name vistrutide is not used in the identified authoritative trial records or developer announcements, and an official INN, molecular sequence, molecular formula, molecular weight, CAS number, and PubChem record were not verified.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Administration Routes (Research)

Subcutaneous injection; once-weekly administration was used in the cited phase 2 studies.

Reported Research Effects

Agonism at the GLP-1 receptor, GIP receptor, and glucagon receptor, as described by the developer and clinical-study publication.
In a phase 2 obesity study, once-weekly subcutaneous UBT251 produced least-squares mean body-weight reductions of 13.6% to 19.7% at week 24 across studied regimens versus 2.0% with placebo.
In the cited phase 2 obesity study, gastrointestinal disorders were the most frequent reported adverse-event category and were primarily mild to moderate in severity.

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Evidence currently consists primarily of clinical-trial registry records, a 2026 American Diabetes Association abstract, and developer announcements. Reported phase 2 obesity regimens included once-weekly subcutaneous doses of 2.0 mg, 4.0 mg with initial doses of 0.5 mg or 1.0 mg, and 6.0 mg for 24 weeks. These are study-regimen details, not prescribing or self-administration guidance. The public sources reviewed did not establish a validated relationship between the name vistrutide and the official compound name UBT251.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

Development code: UBT251; ClinicalTrials.gov identifiers include NCT07134335 and NCT07668388. No CAS number, PubChem CID, molecular sequence, molecular formula, or molecular weight was verified.

Source-Backed Observations

The requested name vistrutide could not be confirmed as an official nonproprietary name or authoritative development name. The authoritative record concerns UBT251. No publicly verified molecular structure or peptide sequence was identified. UBT251 remains investigational and was described by ClinicalTrials.gov as not available for prescribing in the referenced study record.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study
https://clinicaltrials.gov/study/NCT07668388 (accessed 2026-09-20)

UBT251 Injection Phase II Clinical Study (CKD)
https://clinicaltrials.gov/study/NCT07134335 (accessed 2026-09-20)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.